Research CHAIR

Pioneering the Future of Muscular Dystrophy Research at the University of Alberta

Garrett Cumming was only three years old when he was diagnosed with Duchenne Muscular Dystrophy (DMD), the most common and severe form of muscular dystrophy that typically affects boys, leading to progressively worsening muscle degeneration and premature death. Moved by Garrett’s resilience and the plight of many others facing similar challenges, his family, including his father James Cumming—a Member of Parliament in Canada—sought to create a lasting impact. Their collaborative efforts with Muscular Dystrophy Canada led to the establishment of the Friends of Garrett Cumming Research Chair at the University of Alberta, marking the first endowed chair in Canada dedicated solely to muscular dystrophy research.

The Friends of Garrett Cumming Research Chair at the University of Alberta, established in partnership with Muscular Dystrophy Canada (MDC) in 2011, represents a monumental effort in advancing the scientific quest to cure neuromuscular disorders. Named in honour of Garrett Cumming, who bravely fought DMD until his passing in 2021, the chair was created thanks to the tireless fundraising efforts of his family, friends, and community, who collectively raised over $1.6 million. This amount was further matched dollar for dollar by $1.5 million from the Government of Alberta’s Access to the Future Fund, illustrating a stellar example of community and governmental collaboration.

Leading a Legacy of Innovation

In 2011, the distinguished chair was appointed to Dr. Toshifumi Yokota, bringing expertise and innovative vision to the forefront of genetic therapy. Under the leadership of the Friends of Garrett Cumming Research Chair, the Yokota Lab has become a beacon of hope, making significant strides in understanding and treating rare neuromuscular disorders. The lab's work has pioneered a groundbreaking approach that enhances the production of healthy proteins in patients with DMD, potentially transforming their lives by shifting the balance from wheelchair dependence to increased mobility and possibly extending life expectancy significantly.

Breakthroughs and Impact

The research spearheaded by Dr. Yokota has led to the development of Viltolarsen, a novel antisense oligonucleotide therapy that is now FDA-approved for DMD treatment. This therapy is a testament to the lab’s commitment to "bench to bedside" research, where scientific discoveries are rapidly translated into clinical applications that can have an immediate positive impact on patients' lives.

The Yokota Lab continues to explore the potential of gene therapies and other innovative strategies to combat DMD and other similar genetic disorders. With a focus on precision medicine and next-generation treatments, the lab collaborates with pharmaceutical leaders and academic institutions worldwide to push the boundaries of medical science.

Envisioning a Brighter Future

Thanks to the enduring support of the Friends of Garrett Cumming and Muscular Dystrophy Canada, along with the passionate commitment of donors and the community, the research chair not only honours Garrett's legacy but also ignites progressive advancements in medical research. These efforts are paving the way for a future where muscular dystrophy and other neuromuscular disorders can be effectively managed or even cured.

As the Friends of Garrett Cumming Research Chair, Dr. Yokota embodies the spirit of innovation and compassion, striving each day to unlock new possibilities for treatment and hope for thousands of patients worldwide. The Yokota Lab is more than just a research facility; it's a place where science meets humanity, where every breakthrough brings us one step closer to a cure.

Discover Our Latest Progress

The 2024 Annual Report is now available below!